paastoinsuliini

Paastoinsuliini refers to insulin that is administered to individuals during fasting periods, most commonly overnight. It is a type of basal insulin, meaning it is designed to provide a steady, long-acting background level of insulin throughout the day and night. The primary purpose of paastoinsuliini is to prevent hyperglycemia, or high blood sugar, that can occur during fasting due to the liver releasing stored glucose into the bloodstream.

This type of insulin is particularly important for people with type 1 diabetes, where the body produces little or no insulin, and for some individuals with type 2 diabetes who require insulin therapy. By providing a consistent insulin supply, paastoinsuliini helps to maintain blood glucose levels within a target range, reducing the risk of nocturnal hypoglycemia (low blood sugar) and morning hyperglycemia.

The dosage and type of paastoinsuliini are individualized based on factors such as the patient's overall insulin needs, blood glucose monitoring results, and the duration of the fasting period. It is typically administered once daily, often before bedtime, and its effects last for approximately 24 hours. Healthcare professionals play a crucial role in determining the appropriate insulin regimen, including the use of paastoinsuliini, to ensure safe and effective diabetes management. Regular monitoring of blood glucose is essential to adjust dosages as needed.